Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

New Hope for a Once Hopeless Diagnosis: Small Cell Lung Cancer

By: NewsUSA

(Diane Mulligan) - Small cell lung cancer (SCLC) is among the most aggressive, deadliest forms of lung cancer, yet it’s still too often overlooked. For decades, treatment options were limited, offering little hope to those diagnosed with SCLC, until now.

In 2013, Congress passed legislation that mandated the National Cancer Institute create a scientific plan for treating patients with less than a 50% chance of surviving 5 years. This included SCLC. With this focus on research, SCLC, once considered a hopeless diagnosis because of its swift spread and resistance to standard treatment, is now seeing real momentum. Breakthrough research has increased the number of treatment options by 67% giving doctors new tools and patients new reasons to hope.

Jacob SandsBecause of research, treatments like the recently FDA-approved Tarlatamab belong to a class of drugs called bispecific T-cell engagers (BiTEs), which harness the immune system to combat cancer. Another treatment, Lurbinectedin, slows or stops the growth of cancer cells in your body.  There are also next-generation approaches, such as CAR T-cell therapy and antibody-drug conjugates, and many others, now in clinical trials. Clinical trials, once a last resort, are rapidly becoming a front door to tomorrow’s breakthroughs.

Early detection is critical. Screening is the best way to find SCLC early.

Wendy Brooks knows this firsthand. Wendy had a history of lung cancer in her family. She pushed hard to get screened, and her cancer was caught early, rare for this disease. Through two clinical trials, Wendy has kept the cancer confined to her lung and is living fully. She credits screening and participating in clinical trials with saving her life.

“I’m here today because of research,” Wendy says. “I want others to know there’s hope, and clinical trials can be a lifeline.”

Thoracic oncologist Dr. Jacob Sands echoes that optimism: “I have patients more than five years out from that initial diagnosis doing great, living their lives and not on treatment. And I’ll go as far as to say that I think some patients are cured of their incurable disease.”

Lung Cancer Foundation of America (LCFA) is raising awareness of the lifesaving power of early screening, new treatments, and the growing promise of clinical trials for people facing SCLC.

LCFA is a nonprofit organization dedicated to eradicating lung cancer through research, education, and awareness programs. Committed to improving patient outcomes, donations to LCFA fund innovative research projects, educational initiatives, and advocacy for increased resources for lung cancer research.

Donate today to fight Lung Cancer at LCFAmerica.org

 

**Image Captions: 
Wendy Brooks, Lung Cancer Patient (header image)
Dr. Jacob Sands, Thoracic Oncologist at Dana-Farber Cancer Institute

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.